Abbott Laboratories (ABT) 37.02 $ABT
Abbott Labs Progresses with Absorb - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 4:40PM CDT
Abbott Laboratories (ABT) announced that it has completed enrollment of three clinical trials on Absorb, a drug-eluting coronary bioresorbable vascular scaffold (BVS).
GCC Local Anaesthesia Market 2012-17: Articaine, Bupivacaine, Lidocaine, Mepivacaine, Prilocaine Analysis
M2 - Fri Apr 11, 9:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lznwgp/market_for_local) has announced the addition of the "GCC Local Anaesthesia Market 2012-17: Articaine - Bupivacaine - Lidocaine - Mepivacaine - Prilocaine Analysis" report to their offering. This report focuses on the market for local anaesthetic products in the GCC region. The market is strictly limited to application in human beings and comprises of products administered through injectables and topicals. Local anaesthetic products find applications in vast range of medical surgeries with some popular ones being dentistry, child birth, circumcision etc. Sharp rise in population within the GCC region coupled with rise in per capita income has resulted in increased incidence of surgeries that involves usage of LA. In 2012, market for LA drugs in GCC was valued at USD 14.2 Mn. Saudi Arabia and UAE were the main markets in region contributing to more than 75% of demand. At present, large part of this demand is catered by MNCs which import these drugs from their manufacturing facilities in EU. Domestic production is limited to few regional players in KSA and Kuwait. Going forward, demand for LA is projected to remain strong in the region with Qatar and UAE showing promising growth. Expanding health infrastructure, higher health care spend and increasing disease incidences indicates the need and potential for LA drugs in the region. A detailed analysis of end use growth trends and LA usage trend across each end use categories have been presented to identify drivers and constraints end use wise. Products Mentioned: - Articaine - Bupivacaine - Lidocaine - Mepivacaine - Prilocaine Key Topics Covered: 1. Introduction 2. Glossary of terms 3. GCC Market Analysis 4. Bahrain LA Market Analysis 5. Kingdom of Saudi Arabia (KSA) LA Market Analysis 6. Kuwait LA Market Analysis 7. Oman LA Market Analysis 8. Qatar LA Market Analysis 9. UAE LA Market Analysis Companies Mentioned - Abbott Laboratories - Astra Zeneca - Julphar - Kuwait Saudi Pharmaceutical Industries Company - Novocol - Pharma Solutions Industries - Riyadh Pharma - Septodont For more information visit http://www.researchandmarkets.com/research/lz..._for_local
Healthcare Companies Enter into Acquisitions and Partnerships, Receive FDA Approvals, Make Appointments, and Receive Recognitions - Analyst Notes on Nordion, Abbott, Covidien, DaVita, and Sirona
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Nordion Inc. (NYSE: NDZ), Abbott Laboratories (NYSE: ABT), Covidien plc (NYSE: COV), DaVita HealthCare Partners Inc. (NYSE: DVA), and Sirona Dental Systems Inc. (NASDAQ: SIRO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Research and Markets: Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo Health Solutions, Pfizer & Purdue Pharma Dominating
Business Wire - Fri Apr 11, 6:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7jfkk5/global_pain) has announced the addition of the "Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo health Solutions, Pfizer & Purdue Pharma Dominating" report to their offering.
Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo Health Solutions, Pfizer & Purdue Pharma Dominating
M2 - Fri Apr 11, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjv7jj/global_pain) has announced the addition of the "Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo health Solutions, Pfizer & Purdue Pharma Dominating" report to their offering. The Global Pain Management Drugs market will grow at a CAGR of 3.84 percent over the period 2013-2018. One of the main drivers in this market is the increase in global aging population. The rise in aging population has consequently led to an increase in the incidence of diseases such as chronic arthritis, diabetic neuropathy, osteoarthritis, and cancer. R&D activities are increasing due to the strong need for new efficacious and better-tolerated medications. Developing better pain treatments is the main goal of all pain research being conducted by various institutes. Morphine is one such drug that works through the body's natural pain-killing machinery, preventing pain messages from reaching the brain. Patients receiving morphine also face the problem of morphine tolerance. Scientists are working toward the development of a morphine-like drug that will have the pain-deadening qualities of morphine but without the drug's negative side effects, such as sedation and the potential for addiction. Further, the report states that one of the main challenges is the increase in generic competition. The patent expiry of a drug results in the loss of the exclusive market for that drug, leading to a rapid decline in sales. The key vendors dominating this space are: - Abbott Laboratories - Eli Lilly and Co. - Endo Health Solutions Inc. - Pfizer Inc. - Purdue Pharma L.P. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Category - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis Other Companies Featured: - Actavis plc - Allergen Inc. - Astra Zenca plc - Baxter International Inc. - Bayer Healthcare AG - Boehringer Ingelheim GmbH - Boston Scientific Corp. - Bristol Myers Squibb Co. - Durect Corp. - F. Hoffmann La Roche Ltd. - Forest Laboratories Inc. - GlaxoSmithKline plc - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Novartis AG - Pain Therapeutics Inc. - Sanofi S.A. - St. Jude Medical Inc. - UCB S.A. - Valeant Pharmaceuticals International Inc. - Zalicus Inc. For more information visit http://www.researchandmarkets.com/research/bj...lobal_pain
Singapore and Malaysia In-Vitro Diagnostics (IVD) Market Report 2014
M2 - Fri Apr 11, 3:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3328qv/vd_in_singapore) has announced the addition of the "VD in Singapore and Malaysia" report to their offering. IVD manufacturers seeking marginal growth are focusing on regional markets. The whole of Southeast Asia represents a unique opportunity for healthcare providers and their various industry suppliers, including the in vitro diagnostics (IVD) industry. In this report two nations are detailed that are expected to provide opportunity for IVD manufacturers: Singapore and Malaysia. The nexus of regional trade, and a leading port and center for the entire Asia-Pacific, is Singapore. The city-state features the most developed and highest rated healthcare system in Southeast Asia and serves as the headquarters and regional manufacturing center for some medical device, biotechnology, IVD, and pharmaceutical companies. Its neighbor Malaysia, an upper middle-income nation has arguably the second-most developed healthcare system in Southeast Asia. Through Singapore or Kuala Lumpur, IVD companies have access to approximately 35 million potential patients, over 700,000 annual medical tourists, and healthcare systems with higher per capita spending than anywhere else in Southeast Asia or anywhere in Asia outside of Japan, Australia, or Korea. Singapore and Malaysia present IVD markets and opportunities with healthy prospects and solid fundaments in clinical demand. This IVD in Singapore and Malaysia report contains the following data: - Healthcare Statistics for Singapore and Malaysia - Significant Hospitals in Both Countries - The Lab Market in Singapore and Malaysia Key Topics Covered: Chapter One: Introduction - The IVD Markets of Singapore and Malaysia - Singaporean Healthcare System - Health Status of Singaporeans - Health Status of Malaysians Chapter Two: IVD Market Analysis - Clinical Chemistry - Microbiology, ID/AST and Molecular - Point of Care Testing - Immunoassays - Urinalysis - Molecular Testing - Coagulation - Histology - Hematology - Blood Testing and Typing - Flow Cytometry - Total IVD Markets In Singapore and Malaysia Chapter Three: IVD Companies And Market Leaders - Abbott Laboratories (Singapore) Pte Ltd - Beckman Coulter Singapore Pte Ltd - Becton Dickinson Medical (Singapore) Pte Ltd - Bio-Rad Laboratories (Singapore) Pte Ltd - bioM?rieux Singapore Pte Ltd - Life Technologies Holdings Pte Ltd - Roche Diagnostics Asia Pacific Pte Ltd - Siemens Healthcare Diagnostics Pte Ltd - Sysmex Asia Pacific Pte Ltd - Affymetrix Singapore Pte Ltd - ClearBridge BioLoc Pte Ltd - ClearBridge BioMedics Pte Ltd - Innogene Kalbiotech Pte Ltd - MP Biomedicals Asia Pacific Pte Ltd - PathGEN Dx Pte Ltd - Sentec Pte Ltd - Vela Diagnostics - Volition Pte Ltd For more information visit http://www.researchandmarkets.com/research/33..._singapore
Economics of the TeraStack Solution by Hie Electronics is Validated by Facebook Blu-ray Storage Prototype
PRWeb - Fri Apr 11, 2:21AM CDT
Hie Electronics, a pioneer of innovation for long-term, scalable data storage solutions and the manufacturer of the TeraStack(R) Solution, announced today that the economics of their product line has been validated by Facebook's Blu-ray cold storage prototype.
A Make or Break Week for Q1 Earnings Season - Earnings Preview
Sheraz Mian - ZACKS - Fri Apr 11, 1:43AM CDT
A Make or Break Week for Q1 Earnings Season - Earnings Preview
Earning Release Schedules, Company Updates, Stock Price Movements, and Survey Results - Analyst Notes on Abbott, Humana, United Technologies, 3M, and Ingersoll-Rand
PR Newswire - Thu Apr 10, 9:56AM CDT
Today, Analysts Review released its analysts' notes regarding Abbott Laboratories (NYSE: ABT), Humana Inc. (NYSE: HUM), United Technologies Corporation (NYSE: UTX), 3M Company (NYSE: MMM), and Ingersoll-Rand Plc (NYSE: IR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Hemoglobin A1c Monitoring (HbA1c Laboratory Testing, and HbA1c Point of Care Testing) Market - Global Strategic Overview 2014
M2 - Thu Apr 10, 9:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bxd8pr/hemoglobin_a1c) has announced the addition of the "Hemoglobin A1c Monitoring - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Hemoglobin A1c Monitoring in US$ Million by the following Test Types: HbA1c Laboratory Testing, and HbA1c Point of Care Testing. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 27 companies including many key and niche players such as - Abbott Laboratories (US) - ARKRAY, Inc. (Japan) - Axis-Shield plc (UK) - Bayer Healthcare Diabetes Care (US) - Beckman Coulter, Inc. (US) - Bio-Rad Laboratories Inc (US) - Diazyme Laboratories Inc. (US) - EKF Diagnostics Holdings Plc (UK) - HEMOCUE? AB (Sweden) - Infopia Co. Ltd. (South Korea) - Menarini Diagnostics Ltd. (UK) - Roche Diagnostics (Switzerland) - Siemens Healthcare Diagnostics (Germany) - Tosoh Bioscience, Inc (US) - Trinity Biotech plc (Ireland) Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Market Overview 2. Diabetes A Brief Profile Of The Disease 3. Product Overview 4. Product Approvals/Introductions 5. Recent Industry Activity 6. Focus On Select Players 7. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 27 (including Divisions/Subsidiaries 35) - The United States (14) - Canada (1) - Japan (3) - Europe (14) - Germany (3) - The United Kingdom (5) - Italy (1) - Rest of Europe (5) - Asia-Pacific (Excluding Japan) (3) For more information visit http://www.researchandmarkets.com/research/bx...globin_a1c
Abbott Completes Enrollment of Absorb(TM) Randomized Clinical Trials in the United States, Japan and China
PR Newswire Europe - Thu Apr 10, 7:31AM CDT
- First-of-its-Kind Dissolving Medical Device Being Evaluated in People with Blocked Heart Vessels
Financial Release Schedule -- Research on Abbott Laboratories, PNC, American Express, and Plexus
PR Newswire - Wed Apr 09, 9:58AM CDT
Earnings Source provides investors with earnings schedule updates throughout the earnings season. With timely information on past earnings performance and earnings projection for their upcoming quarterly release, our aim is to ensure shareholders and traders have an edge on their investment decisions on the following companies: Abbott Laboratories (NYSE: ABT), The PNC Financial Services Group Inc. (NYSE: PNC), American Express Company (NYSE: AXP) and Plexus Corporation (NASDAQ: PLXS). Full earnings notes on ABT, PNC, AXP and PLXS can be downloaded upon signing up at:
Global Insulin Delivery Devices Market to 2019
M2 - Wed Apr 09, 8:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h59w23/insulin_delivery) has announced the addition of the "Insulin Delivery Devices Market to 2019 - Simplified Pump Solutions and Low Cost Pens Represent Distinct Regional Growth Drivers" report to their offering. The global insulin delivery devices market was valued at $8.8 billion in 2012 and is forecast to reach $13.8 billion by 2019, at a CAGR of 7%. Simplified Pump Solutions and Low Cost Pens Represent Distinct Regional Growth Drivers Growth in developed economies such as the US and Europe is attributed to an increasing preference for insulin pumps and the uptake of technical advances such as artificial pancreas devices. Supply-side initiatives aim to develop artificial pancreas devices that closely mimic the pancreas by using rapid-acting insulin and multiple hormone-secreting devices for the effective control of blood glucose. The growth in developing economies is attributed to the high prevalence of diabetes and low penetration of insulin delivery devices in these countries. Collaborations among companies and research foundations such as the Juvenile Diabetes Research Foundation (JDRF) help foster innovation in the diabetes care devices market. Many of these collaborations aim to develop artificial pancreas devices that can effectively replace the pancreas, ensuring the effective management of diabetes. Emerging economies such as India and China are expected to grow at the fastest pace during the 2012-2019 forecast period. While developed economies will witness increasing uptake of technically advanced devices, emerging economies will continue to see increasing uptake for conventional insulin delivery devices such as insulin pens, due to their lower cost." Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Diabetes - Disease Overview 4 Diabetes - Epidemiology 5 Global Insulin Delivery Devices Market: Device Overview 6 Global Insulin Delivery Devices Market: Market Characterization 7 Global Insulin Delivery Devices Market: Segment Analysis and Forecasts 8 Global Insulin Delivery Devices Market: Country Analysis and Forecasts 9 Global Insulin Delivery Devices Market: Reimbursement System 10 Global Insulin Delivery Devices Market: Competitive Landscape Companies Mentioned - Abbott Laboratories - Animas - Antares Pharma - Asante Solutions - Becton, Dickinson and Company - Bioject Medical Technologies - Eli Lilly - F. Hoffmann-La Roche - Injex - Equidyne Systems - Insulet - Medtronic - Novo Nordisk (Subsidiary of Novo A/S) - Owen Mumford - Sanofi - Shanghai Fosun Pharmaceutical - Tandem Diabetes Care - Tonghua Dongbao Pharmaceutical - Ypsomed For more information visit http://www.researchandmarkets.com/research/h5...n_delivery
RBCC and n3D Seek Out Additional Capital
Business Wire - Wed Apr 09, 4:00AM CDT
Rainbow Coral Corp. (OTCBB: RBCC) and its joint venture partner, Nano3D Biosciences (n3D) are seeking out new finance partners to market and develop their 3D bioprinting technology worldwide.
Watch for Abbott Laboratories to Potentially Rebound After Falling 1.44% Yesterday
Comtex SmarTrend(R) - Tue Apr 08, 3:58PM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $37.59 to a high of $38.20. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $38.09 on volume of 9.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Abbott Laboratories (ABT) Approaches New Downside Target of $37.62
Comtex SmarTrend(R) - Tue Apr 08, 10:16AM CDT
Shares of Abbott Laboratories (NYSE:ABT) opened today below their pivot of $38.37 and have already reached the first level of support at $37.89. Should the shares continue to fall, the support pivots of $37.62 and $36.87 will be of interest.
United States Coronary Stent Industry Report 2014-2018 - Bioabsorbable Stents to Drive the Future Growth
M2 - Tue Apr 08, 4:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wpgfqz/the_us_coronary) has announced the addition of the "The US Coronary Stent Industry Outlook to 2018 - Bioabsorbable Stents to Drive the Future Growth" report to their offering. The report titled The US Coronary Stent Industry Outlook to 2018 - Bioabsorbable Stents to Drive the Future Growth provides a comprehensive analysis of the various aspects such as the market size of the US Coronary Stent industry, market segments i.e. drug eluting and bare metal stents and future outlook of the industry. The report also covers the market share of major players in the US. KEY TOPICS COVERED IN THE REPORT - The market size of the US coronary stent, drug eluting and bare metal stent industry. - Market segmentation of the US coronary stent market on the basis of types of stents. - Market overview and evolution of Bio-absorbable stent market in the US. - Trends and Developments in the US coronary stent industry. - Competitive landscape and company profiles of the major players of the US coronary stent market. - Market share of leading players on the basis of revenues from coronary stents in the US. - SWOT Analysis of the US coronary stent market. - Analyst Recommendation for the companies and sector - Future outlook and projections of the US coronary stent market. Key Topics Covered: 1. The US Coronary Stent Market Introduction 2. The US Coronary Stent Market Size, 2007-2012 3. The US Coronary Stent Market Segmentation, 2007-2012 4. The US Drug Eluting Stent Market Introduction 5. The US Bare Metal Stent Market Introduction 6. Bioabsorbable Stents in the US: Evolvement and Overview 7. The US Coronary Stent Market Trends and Developments 8. SWOT Analysis of the US Coronary Stent Market 9. Regulatory Environment in Coronary Stent Market in The US 10. Market Share of Major Players in the US Coronary Stent Market, 2007-2012 11. Competitive Landscape of Major Players in the US Coronary Stent Market 12. The US Coronary Stent Market Future Outlook and Projections, 2013-2018 13. Analyst Recommendation 14. Macroeconomic Factors of the US Coronary Stent Market: Historical and Projections 15. Appendix Companies Mentioned - Abbott Laboratories - Boston Scientific - Johnson and Johnson and Medtronic For more information visit http://www.researchandmarkets.com/research/wp...s_coronary
Abbott Laboratories (ABT) Approaches New Upside Target of $39.02
Comtex SmarTrend(R) - Fri Apr 04, 1:01PM CDT
Shares of Abbott Laboratories (NYSE:ABT) opened today above their pivot of $38.57 and have already reached the first level of resistance at $38.83. Should the shares continue to rise, the resistance pivots of $39.02 and $39.47 will be of interest.
Abbott Labs Progresses with Absorb - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 4:40PM CDT
Abbott Laboratories (ABT) announced that it has completed enrollment of three clinical trials on Absorb, a drug-eluting coronary bioresorbable vascular scaffold (BVS).
GCC Local Anaesthesia Market 2012-17: Articaine, Bupivacaine, Lidocaine, Mepivacaine, Prilocaine Analysis
M2 - Fri Apr 11, 9:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lznwgp/market_for_local) has announced the addition of the "GCC Local Anaesthesia Market 2012-17: Articaine - Bupivacaine - Lidocaine - Mepivacaine - Prilocaine Analysis" report to their offering. This report focuses on the market for local anaesthetic products in the GCC region. The market is strictly limited to application in human beings and comprises of products administered through injectables and topicals. Local anaesthetic products find applications in vast range of medical surgeries with some popular ones being dentistry, child birth, circumcision etc. Sharp rise in population within the GCC region coupled with rise in per capita income has resulted in increased incidence of surgeries that involves usage of LA. In 2012, market for LA drugs in GCC was valued at USD 14.2 Mn. Saudi Arabia and UAE were the main markets in region contributing to more than 75% of demand. At present, large part of this demand is catered by MNCs which import these drugs from their manufacturing facilities in EU. Domestic production is limited to few regional players in KSA and Kuwait. Going forward, demand for LA is projected to remain strong in the region with Qatar and UAE showing promising growth. Expanding health infrastructure, higher health care spend and increasing disease incidences indicates the need and potential for LA drugs in the region. A detailed analysis of end use growth trends and LA usage trend across each end use categories have been presented to identify drivers and constraints end use wise. Products Mentioned: - Articaine - Bupivacaine - Lidocaine - Mepivacaine - Prilocaine Key Topics Covered: 1. Introduction 2. Glossary of terms 3. GCC Market Analysis 4. Bahrain LA Market Analysis 5. Kingdom of Saudi Arabia (KSA) LA Market Analysis 6. Kuwait LA Market Analysis 7. Oman LA Market Analysis 8. Qatar LA Market Analysis 9. UAE LA Market Analysis Companies Mentioned - Abbott Laboratories - Astra Zeneca - Julphar - Kuwait Saudi Pharmaceutical Industries Company - Novocol - Pharma Solutions Industries - Riyadh Pharma - Septodont For more information visit http://www.researchandmarkets.com/research/lz..._for_local
Healthcare Companies Enter into Acquisitions and Partnerships, Receive FDA Approvals, Make Appointments, and Receive Recognitions - Analyst Notes on Nordion, Abbott, Covidien, DaVita, and Sirona
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Nordion Inc. (NYSE: NDZ), Abbott Laboratories (NYSE: ABT), Covidien plc (NYSE: COV), DaVita HealthCare Partners Inc. (NYSE: DVA), and Sirona Dental Systems Inc. (NASDAQ: SIRO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Research and Markets: Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo Health Solutions, Pfizer & Purdue Pharma Dominating
Business Wire - Fri Apr 11, 6:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7jfkk5/global_pain) has announced the addition of the "Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo health Solutions, Pfizer & Purdue Pharma Dominating" report to their offering.
Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo Health Solutions, Pfizer & Purdue Pharma Dominating
M2 - Fri Apr 11, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjv7jj/global_pain) has announced the addition of the "Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo health Solutions, Pfizer & Purdue Pharma Dominating" report to their offering. The Global Pain Management Drugs market will grow at a CAGR of 3.84 percent over the period 2013-2018. One of the main drivers in this market is the increase in global aging population. The rise in aging population has consequently led to an increase in the incidence of diseases such as chronic arthritis, diabetic neuropathy, osteoarthritis, and cancer. R&D activities are increasing due to the strong need for new efficacious and better-tolerated medications. Developing better pain treatments is the main goal of all pain research being conducted by various institutes. Morphine is one such drug that works through the body's natural pain-killing machinery, preventing pain messages from reaching the brain. Patients receiving morphine also face the problem of morphine tolerance. Scientists are working toward the development of a morphine-like drug that will have the pain-deadening qualities of morphine but without the drug's negative side effects, such as sedation and the potential for addiction. Further, the report states that one of the main challenges is the increase in generic competition. The patent expiry of a drug results in the loss of the exclusive market for that drug, leading to a rapid decline in sales. The key vendors dominating this space are: - Abbott Laboratories - Eli Lilly and Co. - Endo Health Solutions Inc. - Pfizer Inc. - Purdue Pharma L.P. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Category - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis Other Companies Featured: - Actavis plc - Allergen Inc. - Astra Zenca plc - Baxter International Inc. - Bayer Healthcare AG - Boehringer Ingelheim GmbH - Boston Scientific Corp. - Bristol Myers Squibb Co. - Durect Corp. - F. Hoffmann La Roche Ltd. - Forest Laboratories Inc. - GlaxoSmithKline plc - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Novartis AG - Pain Therapeutics Inc. - Sanofi S.A. - St. Jude Medical Inc. - UCB S.A. - Valeant Pharmaceuticals International Inc. - Zalicus Inc. For more information visit http://www.researchandmarkets.com/research/bj...lobal_pain
Singapore and Malaysia In-Vitro Diagnostics (IVD) Market Report 2014
M2 - Fri Apr 11, 3:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3328qv/vd_in_singapore) has announced the addition of the "VD in Singapore and Malaysia" report to their offering. IVD manufacturers seeking marginal growth are focusing on regional markets. The whole of Southeast Asia represents a unique opportunity for healthcare providers and their various industry suppliers, including the in vitro diagnostics (IVD) industry. In this report two nations are detailed that are expected to provide opportunity for IVD manufacturers: Singapore and Malaysia. The nexus of regional trade, and a leading port and center for the entire Asia-Pacific, is Singapore. The city-state features the most developed and highest rated healthcare system in Southeast Asia and serves as the headquarters and regional manufacturing center for some medical device, biotechnology, IVD, and pharmaceutical companies. Its neighbor Malaysia, an upper middle-income nation has arguably the second-most developed healthcare system in Southeast Asia. Through Singapore or Kuala Lumpur, IVD companies have access to approximately 35 million potential patients, over 700,000 annual medical tourists, and healthcare systems with higher per capita spending than anywhere else in Southeast Asia or anywhere in Asia outside of Japan, Australia, or Korea. Singapore and Malaysia present IVD markets and opportunities with healthy prospects and solid fundaments in clinical demand. This IVD in Singapore and Malaysia report contains the following data: - Healthcare Statistics for Singapore and Malaysia - Significant Hospitals in Both Countries - The Lab Market in Singapore and Malaysia Key Topics Covered: Chapter One: Introduction - The IVD Markets of Singapore and Malaysia - Singaporean Healthcare System - Health Status of Singaporeans - Health Status of Malaysians Chapter Two: IVD Market Analysis - Clinical Chemistry - Microbiology, ID/AST and Molecular - Point of Care Testing - Immunoassays - Urinalysis - Molecular Testing - Coagulation - Histology - Hematology - Blood Testing and Typing - Flow Cytometry - Total IVD Markets In Singapore and Malaysia Chapter Three: IVD Companies And Market Leaders - Abbott Laboratories (Singapore) Pte Ltd - Beckman Coulter Singapore Pte Ltd - Becton Dickinson Medical (Singapore) Pte Ltd - Bio-Rad Laboratories (Singapore) Pte Ltd - bioM?rieux Singapore Pte Ltd - Life Technologies Holdings Pte Ltd - Roche Diagnostics Asia Pacific Pte Ltd - Siemens Healthcare Diagnostics Pte Ltd - Sysmex Asia Pacific Pte Ltd - Affymetrix Singapore Pte Ltd - ClearBridge BioLoc Pte Ltd - ClearBridge BioMedics Pte Ltd - Innogene Kalbiotech Pte Ltd - MP Biomedicals Asia Pacific Pte Ltd - PathGEN Dx Pte Ltd - Sentec Pte Ltd - Vela Diagnostics - Volition Pte Ltd For more information visit http://www.researchandmarkets.com/research/33..._singapore
Economics of the TeraStack Solution by Hie Electronics is Validated by Facebook Blu-ray Storage Prototype
PRWeb - Fri Apr 11, 2:21AM CDT
Hie Electronics, a pioneer of innovation for long-term, scalable data storage solutions and the manufacturer of the TeraStack(R) Solution, announced today that the economics of their product line has been validated by Facebook's Blu-ray cold storage prototype.
A Make or Break Week for Q1 Earnings Season - Earnings Preview
Sheraz Mian - ZACKS - Fri Apr 11, 1:43AM CDT
A Make or Break Week for Q1 Earnings Season - Earnings Preview
Earning Release Schedules, Company Updates, Stock Price Movements, and Survey Results - Analyst Notes on Abbott, Humana, United Technologies, 3M, and Ingersoll-Rand
PR Newswire - Thu Apr 10, 9:56AM CDT
Today, Analysts Review released its analysts' notes regarding Abbott Laboratories (NYSE: ABT), Humana Inc. (NYSE: HUM), United Technologies Corporation (NYSE: UTX), 3M Company (NYSE: MMM), and Ingersoll-Rand Plc (NYSE: IR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Hemoglobin A1c Monitoring (HbA1c Laboratory Testing, and HbA1c Point of Care Testing) Market - Global Strategic Overview 2014
M2 - Thu Apr 10, 9:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bxd8pr/hemoglobin_a1c) has announced the addition of the "Hemoglobin A1c Monitoring - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Hemoglobin A1c Monitoring in US$ Million by the following Test Types: HbA1c Laboratory Testing, and HbA1c Point of Care Testing. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 27 companies including many key and niche players such as - Abbott Laboratories (US) - ARKRAY, Inc. (Japan) - Axis-Shield plc (UK) - Bayer Healthcare Diabetes Care (US) - Beckman Coulter, Inc. (US) - Bio-Rad Laboratories Inc (US) - Diazyme Laboratories Inc. (US) - EKF Diagnostics Holdings Plc (UK) - HEMOCUE? AB (Sweden) - Infopia Co. Ltd. (South Korea) - Menarini Diagnostics Ltd. (UK) - Roche Diagnostics (Switzerland) - Siemens Healthcare Diagnostics (Germany) - Tosoh Bioscience, Inc (US) - Trinity Biotech plc (Ireland) Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Market Overview 2. Diabetes A Brief Profile Of The Disease 3. Product Overview 4. Product Approvals/Introductions 5. Recent Industry Activity 6. Focus On Select Players 7. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 27 (including Divisions/Subsidiaries 35) - The United States (14) - Canada (1) - Japan (3) - Europe (14) - Germany (3) - The United Kingdom (5) - Italy (1) - Rest of Europe (5) - Asia-Pacific (Excluding Japan) (3) For more information visit http://www.researchandmarkets.com/research/bx...globin_a1c
Abbott Completes Enrollment of Absorb(TM) Randomized Clinical Trials in the United States, Japan and China
PR Newswire Europe - Thu Apr 10, 7:31AM CDT
- First-of-its-Kind Dissolving Medical Device Being Evaluated in People with Blocked Heart Vessels
Financial Release Schedule -- Research on Abbott Laboratories, PNC, American Express, and Plexus
PR Newswire - Wed Apr 09, 9:58AM CDT
Earnings Source provides investors with earnings schedule updates throughout the earnings season. With timely information on past earnings performance and earnings projection for their upcoming quarterly release, our aim is to ensure shareholders and traders have an edge on their investment decisions on the following companies: Abbott Laboratories (NYSE: ABT), The PNC Financial Services Group Inc. (NYSE: PNC), American Express Company (NYSE: AXP) and Plexus Corporation (NASDAQ: PLXS). Full earnings notes on ABT, PNC, AXP and PLXS can be downloaded upon signing up at:
Global Insulin Delivery Devices Market to 2019
M2 - Wed Apr 09, 8:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h59w23/insulin_delivery) has announced the addition of the "Insulin Delivery Devices Market to 2019 - Simplified Pump Solutions and Low Cost Pens Represent Distinct Regional Growth Drivers" report to their offering. The global insulin delivery devices market was valued at $8.8 billion in 2012 and is forecast to reach $13.8 billion by 2019, at a CAGR of 7%. Simplified Pump Solutions and Low Cost Pens Represent Distinct Regional Growth Drivers Growth in developed economies such as the US and Europe is attributed to an increasing preference for insulin pumps and the uptake of technical advances such as artificial pancreas devices. Supply-side initiatives aim to develop artificial pancreas devices that closely mimic the pancreas by using rapid-acting insulin and multiple hormone-secreting devices for the effective control of blood glucose. The growth in developing economies is attributed to the high prevalence of diabetes and low penetration of insulin delivery devices in these countries. Collaborations among companies and research foundations such as the Juvenile Diabetes Research Foundation (JDRF) help foster innovation in the diabetes care devices market. Many of these collaborations aim to develop artificial pancreas devices that can effectively replace the pancreas, ensuring the effective management of diabetes. Emerging economies such as India and China are expected to grow at the fastest pace during the 2012-2019 forecast period. While developed economies will witness increasing uptake of technically advanced devices, emerging economies will continue to see increasing uptake for conventional insulin delivery devices such as insulin pens, due to their lower cost." Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Diabetes - Disease Overview 4 Diabetes - Epidemiology 5 Global Insulin Delivery Devices Market: Device Overview 6 Global Insulin Delivery Devices Market: Market Characterization 7 Global Insulin Delivery Devices Market: Segment Analysis and Forecasts 8 Global Insulin Delivery Devices Market: Country Analysis and Forecasts 9 Global Insulin Delivery Devices Market: Reimbursement System 10 Global Insulin Delivery Devices Market: Competitive Landscape Companies Mentioned - Abbott Laboratories - Animas - Antares Pharma - Asante Solutions - Becton, Dickinson and Company - Bioject Medical Technologies - Eli Lilly - F. Hoffmann-La Roche - Injex - Equidyne Systems - Insulet - Medtronic - Novo Nordisk (Subsidiary of Novo A/S) - Owen Mumford - Sanofi - Shanghai Fosun Pharmaceutical - Tandem Diabetes Care - Tonghua Dongbao Pharmaceutical - Ypsomed For more information visit http://www.researchandmarkets.com/research/h5...n_delivery
RBCC and n3D Seek Out Additional Capital
Business Wire - Wed Apr 09, 4:00AM CDT
Rainbow Coral Corp. (OTCBB: RBCC) and its joint venture partner, Nano3D Biosciences (n3D) are seeking out new finance partners to market and develop their 3D bioprinting technology worldwide.
Watch for Abbott Laboratories to Potentially Rebound After Falling 1.44% Yesterday
Comtex SmarTrend(R) - Tue Apr 08, 3:58PM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $37.59 to a high of $38.20. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $38.09 on volume of 9.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Abbott Laboratories (ABT) Approaches New Downside Target of $37.62
Comtex SmarTrend(R) - Tue Apr 08, 10:16AM CDT
Shares of Abbott Laboratories (NYSE:ABT) opened today below their pivot of $38.37 and have already reached the first level of support at $37.89. Should the shares continue to fall, the support pivots of $37.62 and $36.87 will be of interest.
United States Coronary Stent Industry Report 2014-2018 - Bioabsorbable Stents to Drive the Future Growth
M2 - Tue Apr 08, 4:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wpgfqz/the_us_coronary) has announced the addition of the "The US Coronary Stent Industry Outlook to 2018 - Bioabsorbable Stents to Drive the Future Growth" report to their offering. The report titled The US Coronary Stent Industry Outlook to 2018 - Bioabsorbable Stents to Drive the Future Growth provides a comprehensive analysis of the various aspects such as the market size of the US Coronary Stent industry, market segments i.e. drug eluting and bare metal stents and future outlook of the industry. The report also covers the market share of major players in the US. KEY TOPICS COVERED IN THE REPORT - The market size of the US coronary stent, drug eluting and bare metal stent industry. - Market segmentation of the US coronary stent market on the basis of types of stents. - Market overview and evolution of Bio-absorbable stent market in the US. - Trends and Developments in the US coronary stent industry. - Competitive landscape and company profiles of the major players of the US coronary stent market. - Market share of leading players on the basis of revenues from coronary stents in the US. - SWOT Analysis of the US coronary stent market. - Analyst Recommendation for the companies and sector - Future outlook and projections of the US coronary stent market. Key Topics Covered: 1. The US Coronary Stent Market Introduction 2. The US Coronary Stent Market Size, 2007-2012 3. The US Coronary Stent Market Segmentation, 2007-2012 4. The US Drug Eluting Stent Market Introduction 5. The US Bare Metal Stent Market Introduction 6. Bioabsorbable Stents in the US: Evolvement and Overview 7. The US Coronary Stent Market Trends and Developments 8. SWOT Analysis of the US Coronary Stent Market 9. Regulatory Environment in Coronary Stent Market in The US 10. Market Share of Major Players in the US Coronary Stent Market, 2007-2012 11. Competitive Landscape of Major Players in the US Coronary Stent Market 12. The US Coronary Stent Market Future Outlook and Projections, 2013-2018 13. Analyst Recommendation 14. Macroeconomic Factors of the US Coronary Stent Market: Historical and Projections 15. Appendix Companies Mentioned - Abbott Laboratories - Boston Scientific - Johnson and Johnson and Medtronic For more information visit http://www.researchandmarkets.com/research/wp...s_coronary
Abbott Laboratories (ABT) Approaches New Upside Target of $39.02
Comtex SmarTrend(R) - Fri Apr 04, 1:01PM CDT
Shares of Abbott Laboratories (NYSE:ABT) opened today above their pivot of $38.57 and have already reached the first level of resistance at $38.83. Should the shares continue to rise, the resistance pivots of $39.02 and $39.47 will be of interest.
